Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868121 · ClinicalTrials.gov registry record · NA
AYA OMGYES Sexual Health Study
A NA study of Sexual Dysfunction, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06868121: Recruiting NA study of Sexual Dysfunction, sponsored by University of Chicago.
NCT06868121 is a NA study of Sexual Dysfunction that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 30 participants, below the 966-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868121, a NA study of Sexual Dysfunction, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the impact of the web-based intervention OMGYES.com on sexual dysfunction in young adult (YA) female-bodied cancer survivors. This pilot trial seeks to evaluate the intervention's: * feasibility * acceptability * appropriateness. Researchers will utilize an active observation period to compare outcomes between those receiving the intervention immediately and those who haven't Participants will: * Complete online modules at home * Visit the clinic every 5 weeks for questionnaires
Primary Outcome
The Feasibility of Intervention Measure (FIM) is a validated questionnaire that utilizes a 5-point Likert scale to evaluate the extent at which an intervention can be successfully used in a clinical setting.
Conditions Studied
Interventions
- OTHER OMGYES.com
Study Locations (1)
Illinois
- University of Chicago Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-16 |
| Est. Completion | 2026-05-01 |
| Phase | NA |
What NCT06868121 shows while recruiting
NCT06868121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 966-participant average among 20 other Sexual Dysfunction trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Sexual Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which OMGYES.com is the first listed.
NCT06868121 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06868121 about?
NCT06868121 is a clinical study titled "AYA OMGYES Sexual Health Study". The purpose of this study is to assess the impact of the web-based intervention OMGYES.com on sexual dysfunction in young adult (YA) female-bodied cancer survivors. This pilot trial seeks to evaluate the intervention's: * feasibility * acceptability * appropriateness. Researchers will utilize an a...
What is the current status of trial NCT06868121?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-01-16. Estimated completion is 2026-05-01.
What conditions does trial NCT06868121 study?
This clinical trial studies the following conditions: Sexual Dysfunction.
What interventions are being tested in trial NCT06868121?
The interventions under investigation include: OMGYES.com (OTHER).
Who is sponsoring clinical trial NCT06868121?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868121 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sexual Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06868121's enrollment target sits among peer trials
30 14th of 20 higher than 7 of 20 other Sexual Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sexual Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
RECRUITING · NA
-
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women
RECRUITING · NA
-
Prostate Stimulation for Sexual Dysfunction
RECRUITING · NA
-
Improving Women's Function After Pelvic Radiation
ACTIVE NOT RECRUITING · NA
-
Reducing Alcohol Use and Sexual Dysfunction in Survivors of Sexual Trauma
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI